Galapagos, Gilead
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...
This was the stock's fourth consecutive day of losses.
And other news from Christians around the world.
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
Irish Independent on MSN1d
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealUS biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
This was the stock's third consecutive day of losses.
The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...
The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback